// App-Quantinova.ai

: Nivolumab Treatment Beyond Investigator-Assessed Progression: Extended Follow-up in Patients with Relapsed/Refractory Classical Hodgkin Lymphoma from the Phase 2 CheckMate 205 Study

Researchers

Presenter

  • Jonathon B. Cohen

Principal Investigators

  • John Kuruvilla

  • Andreas Engert

  • Stephen M. Ansell

  • Anas Younes

  • Hun Ju Lee

  • Marek Trnen

  • Kerry J Savage

  • Radhakrishnan Ramchandren

  • Graham P. Collins

  • Pier Luigi Zinzani

  • Jan Paul De Boer

  • Margaret A. Shipp

  • Armando Santoro

  • John M. Timmerman

  • Mariana Sacchi

  • Oumar Sy

  • Philippe Armand

Medical Centers

  • Winship Cancer Institute of Emory University, Atlanta, GA

  • University Health Network, Princess Margaret Cancer Centre, Toronto, ON, Canada

  • University of Cologne, Cologne, DE, Germany

  • Mayo Clinic, Rochester, MN

  • Memorial Sloan Kettering Cancer Center, Port Washington, NY

  • The University of Texas MD Anderson Cancer Canter, Houston, TX

  • Charles University in Prague and General University Hospital in Prague, Prague, Czech Republic

  • British Columbia Cancer Agency, Vancouver, BC, Canada

  • Barbara Ann Karmanos Cancer Institute, Detroit, MI

  • Oxford Cancer and Haematology Centre, Churchill Hospital, Oxford, United Kingdom

  • Institute of Hematology, University of Bologna, Bologna, Italy

  • The Netherlands Cancer Institute, Antoni Van Leeuwenhoek Hospital, Amsterdam, Netherlands

  • Center of Hematologic Oncology, Dana-Farber Cancer Institute, Boston, MA

  • Humanitas Cancer Center, Humanitas University, Rozzano (MI), Italy

  • University of California, Los Angeles, Los Angeles, CA

  • Bristol-Myers Sqiubb, Princeton, NJ

  • Dana-Farber Cancer Institute, Boston, MA

Locations

  • United States

  • Canada

  • Germany

  • Czech Republic

  • United Kingdom

  • Italy

  • Netherlands

Companies

  • N/A

Study Components

Therapeutic Area

  • Oncology (ONC)

Disease

  • Hodgkin's Lymphoma

Biomarkers

  • Programmed cell death protein 1

Drug/Treatment

  • Nivolumab

  • Techniclone TNT

Outcome

  • N/A

Study Design

  • Single Arm

  • Multinational

  • Multicenteric

  • Cohort

Phase

  • II

Study Id's

  • NCT02181738

Sponsors

  • N/A

Result

  • N/A

Copyright © 2026. QuantiNova All rights reserved